Duchenne News Tags: Italfarmaco

November 29, 2023
Italfarmaco announces FDA extended the review process of the New Drug Application for Givinostat.
July 5, 2023
Italfarmaco announces that the FDA has completed filing review and accepted the company’s NDA for Givinostat.
June 27, 2022
On Saturday, June 25, 2022, Italfarmaco Group shared a press release regarding positive topline data from its completed Phase 3 EPIDYS trial with Givinostat.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open